Image pharmaphorum Editor Views & Analysis AI meets RWE: The future of drug assessment? Savana’s Dr Ignacio Medrano explains how machine learning and natural language processing technology is opening up huge amounts of previously-inaccessible real-world evidence (RWE) for phar Views & Analysis How to improve payer engagement with tailored value communic... Pharmaceutical drug success rests on being able to achieve market access. Views & Analysis Listening to ultra-rare disease communities When it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges. Views & Analysis Building honest dialogue with patient advocates How can the industry listen to patients in a way that puts the person behind the disease first? Load more results
Views & Analysis AI meets RWE: The future of drug assessment? Savana’s Dr Ignacio Medrano explains how machine learning and natural language processing technology is opening up huge amounts of previously-inaccessible real-world evidence (RWE) for phar
Views & Analysis How to improve payer engagement with tailored value communic... Pharmaceutical drug success rests on being able to achieve market access.
Views & Analysis Listening to ultra-rare disease communities When it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges.
Views & Analysis Building honest dialogue with patient advocates How can the industry listen to patients in a way that puts the person behind the disease first?
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
